(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -5.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Arcus Biosciences's revenue in 2026 is $236,000,000.On average, 14 Wall Street analysts forecast RCUS's revenue for 2026 to be $11,582,702,035, with the lowest RCUS revenue forecast at $6,212,188,018, and the highest RCUS revenue forecast at $29,053,600,422. On average, 14 Wall Street analysts forecast RCUS's revenue for 2027 to be $15,160,696,947, with the lowest RCUS revenue forecast at $0, and the highest RCUS revenue forecast at $46,808,997,702.
In 2028, RCUS is forecast to generate $26,643,786,638 in revenue, with the lowest revenue forecast at $8,381,523,516 and the highest revenue forecast at $78,012,061,462.